Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KYNU | Q16719 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860398 | 0.85 | LMNA (0.34) | PLA2G2ACYP2C19LMNACA12CA1 | |
| SCHEMBL25669502 | 0.85 | ALDH1A1 (0.38) | PLA2G2ACYP2C19LMNACA12CA1 | |
| SCHEMBL5231692 | 0.83 | KDM4E (0.36) | SMN1; SMN2PLA2G2ACYP2C19LMNACA12 | |
| SCHEMBL2707882 | 0.83 | SMN1; SMN2 (0.33) | SMN1; SMN2CYP2C19LMNACA12CA1 | |
| SCHEMBL21762792 | 0.82 | PLA2G2A (0.36) | SMN1; SMN2PLA2G2ACA12CA1CA2 | |
| SCHEMBL14567507 | 0.82 | CAD (0.33) | SMN1; SMN2CYP2C19LMNACA12CA1 | |
| SCHEMBL9304618 | 0.81 | CYP3A4 (0.41) | SMN1; SMN2PLA2G2ACYP2C19LMNACA12 | |
| SCHEMBL12903898 | 0.81 | MMP1 (0.37) | SMN1; SMN2PLA2G2ACA12CA1CA2 | |
| SCHEMBL6601068 | 0.79 | NPSR1 (0.37) | SMN1; SMN2CYP2C19LMNA | |
| SCHEMBL16869942 | 0.79 | PLA2G2A (0.31) | SMN1; SMN2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428396-B2 | Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-09-30 | — | — | US | disclosed |
| WO-2025136841-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-114929685-B | Fused pyridine ring derivatives, preparation method thereof and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230183180-A1 | PROCESS OF MAKING ROXADUSTAT | SUZHOU PENGXU PHARMATECH CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6416861-B1 | COMBINATORIAL CHEMISTRY | NORTHWESTERN UNIVERSITY | 2002-07-09 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2000049022-A2 | ORGANOSILICON COMPOUNDS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2000-08-24 | — | — | WO | disclosed |
| WO-1996040155-A1 | USE OF SPECIFIC ACPA DERIVATIVE (NPC-17742) FOR THE TREATMENT OF ISCHEMIA | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0639197-B1 | EXCITATORY AMINO ACID ANTAGONISTS | GUILFORD PHARM INC (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0639197-A1 | EXCITATORY AMINO ACID ANTAGONISTS. | GUILFORD PHARM INC (US) | 1995-02-22 | — | — | EP | disclosed |
| EP-0639197-A4 | EXCITATORY AMINO ACID ANTAGONISTS. | GUILFORD PHARM INC (US) | 1994-02-21 | — | — | EP | disclosed |
| US-5256814-A | Anticonvulsant, analgesic, cognition activator | SCIOS NOVA INC. (US) | 1993-10-26 | — | — | US | disclosed |
| WO-1992010099-A1 | EXCITATORY AMINO ACID ANTAGONISTS | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | SMN1; SMN2 3028/4885PLA2G2A 518/4885CYP2C19 1489/4885 |
| US-20230183180-A1 | PROCESS OF MAKING ROXADUSTAT | CYP2B6, UGT1A6, CYP2D6 | SMN1; SMN2 3377/4885PLA2G2A 3891/4885CYP2C19 5/4885 |
| US-12428396-B2 | Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof | CYP4F11, CYP4F8, WEE1 | SMN1; SMN2 4820/4885PLA2G2A 4714/4885CYP2C19 55/4885 |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4861/4885PLA2G2A 2145/4885CYP2C19 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.